Long-Term Results of Below-The-Knee Bypass Using a Prosthetic Graft with a Distal Arteriovenous Fistula Interposition.
Francesco SpinelliGiuseppe RoscitanoDavid BarillàGraziana DeroneAntonio NennaNunzio MontelioneVincenzo CataneseAndrea CutrupiMartina Maria GiambraAlessandra VarràPier Francesco VerouxFrancesco StiloPublished in: Diagnostics (Basel, Switzerland) (2023)
Surgical bypass is the gold standard treatment in patients affected by chronic limb-threatening ischemia in advanced GLASS stages, according to the Global Vascular Guidelines. For patients in whom an autologous graft is not available, a prosthesis could be used with the adjunct of a distal arteriovenous fistula interposition. The aim of this study was to examine the long-term results of below-the-knee surgical revascularization using a prosthesis with the distal adjunct mentioned above. From 2010 to 2020, we performed 159 lower limb below-the-knee surgical revascularizations using a prosthesis with the creation of an arteriovenous fistula interposition on the distal anastomosis. The GLASS stage was 3 in 100% of patients. The primary patency rates were as follows: 86.7% at 1 year, 57.2% at 3 years, and 12.6% at 5 years. The graft thrombosis rates were 17.4% at 1 year, 42.1% at 3 years, and 64.5% at 5 years. The amputation-free survival rates were 79% at 1 year, 76% at 3 years, and 64% at 5 years. PTFE prosthetic bypass for below-the-knee arteries using an arteriovenous fistula interposition is a good solution in patients without an autologous conduit. This technique offers reasonable graft patency and limb salvage rates.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- total knee arthroplasty
- lower limb
- peritoneal dialysis
- knee osteoarthritis
- minimally invasive
- prognostic factors
- mesenchymal stem cells
- free survival
- patient reported outcomes
- cell therapy
- coronary artery disease
- patient reported
- acute coronary syndrome
- clinical practice